Changes to midwives exemptions

Summary

- On 1 July 2011, amending legislation\(^1\) will come into force which enables student midwives to administer medicines on the midwives exemptions list, except controlled drugs, under the direct supervision of a midwife.

- This legislation also updates the range of prescription only medicines that may be sold, supplied or administered by registered midwives in the course of their professional practice.

- This circular takes place with effect from 1 July 2011 and replaces NMC Circular 6/2010.

- This circular should be read in conjunction with the NMC documents:
  - The code: Standards of conduct, performance and ethics for nurses and midwives (NMC, 2008)
  - Midwives rules and standards (NMC, 2004)
  - Standards for medicines management (NMC, 2007).

Background

The Nursing and Midwifery Council (NMC) exists to safeguard the health and well being of the public. We do this by maintaining a register of nurses and midwives and by setting standards for education and practice. This includes setting standards for administration, dispensing and storage of medicines. Midwives may, in the course of their professional practice, supply and administer on their own initiative any of the substances specified in medicines legislation under midwives exemptions.

Under the Medicines Act 1968\(^2\), medicines classified as pharmacy (P) medicines may be sold or supplied only through registered pharmacies by or under the supervision of a pharmacist (section 52).

---

Prescription only medicines (POM) are subject to an additional requirement: they may only be sold or supplied through pharmacies against a prescription from an appropriate practitioner (section 58).

General sale list (GSL) medicines may be sold through retail outlets other than pharmacies as they do not need to be sold or supplied under the supervision of a pharmacist (sections 51 and 53).

**Midwives exemptions**


Registered midwives may supply and administer, on their own initiative, any of the substances that are specified in medicines legislation under midwives exemptions, provided it is in the course of their professional practice. They may do so without the need for a prescription or patient-specific direction (PSD) from a medical practitioner. Provided the requirements of any conditions attached to those exemptions are met, a patient group direction (PGD) is not required. If a medicine is not included in the midwives exemptions then a prescription, or a PSD, or a PGD will be required.

Registered midwives must only supply and administer those medicines, including analgesics, in which they have received the appropriate training as to therapeutic use, dosage, side effects, precautions, contra-indications and methods of administration (*Midwives rules and standards*, 2004).

When supplying or administering medicines under midwives exemptions, midwives must ensure their practice is evidence based. Midwives must be familiar with current guidance published in the British National Formulary (BNF) and British National Formulary for Children.

**Supply and administration of medicinal products outside of their license**

Medicine which is licensed but used outside its licensed indications (commonly known as ‘off label’) may be administered under the midwives exemptions list provided is the following conditions are met:

- There is no appropriately licensed alternative
- There is a sufficient evidence base and/or experience of using the medicine to demonstrate its safety and efficacy
- Midwives should explain to women and their families, in broad terms, the reasons why the medicine is not licensed for the proposed use.
Administration of medicines on midwives exemptions list by student midwives

Standard 17 of the Standards for pre-registration midwifery education (NMC, 2009) states that student midwives must be able at the point of registration to select, acquire and administer safely a range of permitted drugs consistent with legislation, applying knowledge and skills to the situation which pertains at the time. Methods of administration include: oral, intravenous, intramuscular, topical and inhalational.

Previously, medicines legislation was clear that midwives exemptions relate only to registered midwives and that a registered midwife could not delegate any aspect of these exemptions to a student midwife. This amendment allows student midwives to administer medicines on the midwives exemptions list, except controlled drugs, under the direct supervision of a midwife.

Direct supervision means in direct visual contact during which time the midwife observes the act of administration of medicines by a student midwife.

The Medicines and Healthcare products Regulatory Authority (MHRA) require that the midwife supervising the administration of medicines by a student midwife must have undertaken an approved mentorship programme and be a sign off mentor.

Student midwives may not administer controlled drugs but may participate in the checking and preparation of controlled drugs for administration on the midwives exemption list under the direct supervision of a registered midwife.

On 1 July 2011 medicines legislation will be amended to:

1. Enable student midwives to administer medicines on the exemption list, except controlled drugs, under the direct supervision of a midwife.

2. Article 3 substitutes the list of medicines in Parts 1 and 3 of Schedule 5 to the POM Order in order to remove and amend substances from the list of the range of prescription only medicines that may be sold, supplied or administered by registered midwives. These substances are:

   2.1 Oral ergometrine and haemacel which are no longer available in the BNF

   2.2 Lidocaine and lidocaine hydrochloride which for topical use are (P) medicines

   2.3 Cyclizine hydrochloride is replaced with cyclizine lactate

No changes were made to legislation that affects pharmacy medicines or general sales list medicines used in the course of a midwife’s professional practice.
Amendment of the POM Order
The following is an extract from the Amendments Order 2011¹:

3.—(1) The POM Order is amended as follows.

(3) in schedule 5 (exemption for certain persons from section 58(2) of the Act):

   (a) in Part 1 (exemption from restrictions on sale or supply), in column 2, for item 4 substitute:

   “4 Prescription only medicines containing any of the following substances—
   Diclofenac
   Hydrocortisone acetate
   Miconazole
   Nystatin
   Phytomenadione.”

   (b) in Part 3 (exemptions from restriction on administration), in column 2, for the substances listed in item 2 substitute—

   “Adrenaline
   Anti-D immunoglobulin
   Carboprost
   Cyclizine lactate
   Diamorphine
   Ergometrine maleate
   Hartmann’s solution
   Hepatitis B vaccine
   Hepatitis immunoglobulin
   Lidocaine
   Lidocaine hydrochloride
   Morphine
   Naloxone hydrochloride
   Oxytocins, natural and synthetic
   Pethidine hydrochloride
   Phytomenadione
   Prochlorperazine
   Sodium chloride 0.9%.”

The above list will be reviewed by the NMC in collaboration with the MHRA every three years.
Further information and advice

There is no legal definition for standing orders and they do not exist under any medicines legislation (Standards for medicines management, 2007). We recommend that the term standing orders is no longer used and is replaced with the term midwives exemptions.

The midwives exemptions list and advice on use and administration of prescription only medicines is attached at annexe 1 and 2. Midwives are reminded that they have access to all (P) and (GSL) medicines providing it is in the course of their professional practice.

This circular may be reproduced by all to whom it is addressed.

This circular has been issued by

Professor Dickon Weir-Hughes
Chief Executive and Registrar
Nursing and Midwifery Council
Midwives can supply and administer for non-parenteral use prescription only medicines containing any of the following

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Use</th>
<th>Route</th>
<th>NMC advice for professional practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac</td>
<td>Adult</td>
<td>Oral/PR</td>
<td>For postpartum pain relief up to 48 hours after birth</td>
</tr>
<tr>
<td>Hydrocortisone acetate</td>
<td>Adult</td>
<td>Topical</td>
<td>For the treatment of haemorrhoids in the antenatal and postnatal period</td>
</tr>
<tr>
<td>Miconazole</td>
<td>Adult</td>
<td>Topical</td>
<td>For the treatment of thrush</td>
</tr>
<tr>
<td>Nystatin</td>
<td>Neonate</td>
<td>Oral</td>
<td>For the treatment of oral thrush</td>
</tr>
<tr>
<td>Phytomenadione</td>
<td>Neonate</td>
<td>Oral</td>
<td>Prophylactic use to prevent vitamin k deficiency bleeding (haemorrhagic disease of the newborn)</td>
</tr>
</tbody>
</table>
Midwives can administer for parenteral use prescription only medicines containing any of the following

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Use</th>
<th>Route</th>
<th>NMC advice for professional practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenaline 1:1000</td>
<td>Adult</td>
<td>IM</td>
<td>For use in anaphylaxis only</td>
</tr>
<tr>
<td>Anti-D immunoglobulin</td>
<td>Adult</td>
<td>IM</td>
<td>For antenatal and postnatal use to protect against haemolytic disease of the newborn</td>
</tr>
<tr>
<td>Carboprost</td>
<td>Adult</td>
<td>IM</td>
<td>No particular uterotonic drug can be recommended over another for the treatment of postpartum haemorrhage. Treatment combinations for postpartum haemorrhage might include repeat bolus of oxytocin (intravenous), ergometrine (intramuscular, or cautiously intravenously), intramuscular oxytocin with ergometrine (Syntometrine), oxytocin infusion (Syntocinon) or carboprost (intramuscular).</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Use</th>
<th>Route</th>
<th>NMC advice for professional practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclizine Lactate</td>
<td>Adult</td>
<td>IM</td>
<td>For management of actual or potential nausea and vomiting</td>
</tr>
<tr>
<td>Diamorphine</td>
<td>Adult</td>
<td>IM</td>
<td>Diamorphine hydrochloride for pain relief in labour</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>May NOT be administered by a student midwife</td>
</tr>
<tr>
<td>Ergometrine Maleate</td>
<td>Adult</td>
<td>IM/IV</td>
<td>No particular uterotonic drug can be recommended over another for the treatment of postpartum haemorrhage. Treatment combinations for postpartum haemorrhage might include repeat bolus of oxytocin (intravenous), ergometrine (intramuscular, or cautiously intravenously), intramuscular oxytocin with ergometrine (Syntometrine), oxytocin infusion (Syntocinon) or carboprost (intramuscular)².</td>
</tr>
<tr>
<td>Hartmann’s solution</td>
<td>Adult</td>
<td>IV</td>
<td>For maternal resuscitation</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Adult</td>
<td>SC/IM</td>
<td>For use as a local anaesthetic</td>
</tr>
<tr>
<td>Lidocaine Hydrochloride</td>
<td>Adult</td>
<td>SC/IM</td>
<td>For use as a local anaesthetic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Use</th>
<th>Route</th>
<th>NMC advice for professional practice</th>
</tr>
</thead>
</table>
| Morphine                           | Adult IM |       | Morphine sulphate for pain relief in labour  
May NOT be administered by a student midwife |
| Naloxone Hydrochloride             | Adult IM |       | For reversal of respiratory depression resulting from opioid administration |
| Oxytocins, natural and synthetic   | Adult IM/IV |     | For active management of the third stage of labour and treatment of postpartum haemorrhage. No particular uterotonic drug can be recommended over another for the treatment of postpartum haemorrhage. Treatment combinations for postpartum haemorrhage might include repeat bolus of oxytocin (intravenous), ergometrine (intramuscular, or cautiously intravenously), intramuscular oxytocin with ergometrine (Syntometrine), oxytocin infusion (Syntocinon) or carboprost (intramuscular)³. |

³ Taken from the National Collaborating Centre for Women’s and Children’s Health document *Intrapartum care: care of healthy women and their babies during childbirth*. Commissioned by the National Institute for Health and Clinical Excellence (NICE 2007, updated 2008).  
<table>
<thead>
<tr>
<th>Drug name</th>
<th>Use</th>
<th>Route</th>
<th>NMC advice for professional practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pethidine Hydrochloride</td>
<td>Adult</td>
<td>IM</td>
<td>For pain relief in labour \ May NOT be administered by a student midwife</td>
</tr>
<tr>
<td>Prochlorperazine</td>
<td>Adult</td>
<td>IM</td>
<td>For management of actual or potential nausea and vomiting</td>
</tr>
<tr>
<td>Sodium Chloride 0.9%</td>
<td>Adult</td>
<td>IV</td>
<td>For maternal resuscitation and IV flush</td>
</tr>
<tr>
<td>Hepatitis B Vaccine</td>
<td>Neonate</td>
<td>IM</td>
<td>For use in protection against Hepatitis B</td>
</tr>
<tr>
<td>Hepatitis B Immunoglobulin</td>
<td>Neonate</td>
<td>IM</td>
<td>For use in protection against Hepatitis B</td>
</tr>
<tr>
<td>Naloxone Hydrochloride</td>
<td>Neonate</td>
<td>IM</td>
<td>For reversal of respiratory depression resulting from opioid administration to mother</td>
</tr>
<tr>
<td>Phytomenadione</td>
<td>Neonate</td>
<td>IM</td>
<td>Prophylactic use to prevent vitamin k deficiency bleeding (haemorrhagic disease of the newborn)</td>
</tr>
</tbody>
</table>